Q-omics provides the consensus-scored SPATA6L profile across patient tissues and cancer cell-line models. SPATA6L expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SPATA6L is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, SPATA6L RNA expression shows 18,949 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KICH, and UVM as cancer lineages where SPATA6L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPATA6L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPATA6L survival associations across molecular data types. SPATA6L RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPATA6L RNA expression–survival associations across cancer types. High SPATA6L expression shows unfavorable associations in LGG, ACC and UVM, but favorable associations in MESO, BRCA and OV. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for SPATA6L RNA expression.
This table summarizes SPATA6L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SPATA6L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPATA6L shows lower tumor expression in KICH, LUSC, LUAD and BRCA and higher tumor expression in COAD and KIRP. The KICH box plot shows higher SPATA6L RNA expression in normal versus tumor tissue (log2 FC = −0.940, t-test p < 0.001).
This table shows molecular features associated with SPATA6L in patient tissues and cancer cell lines. In patient samples, SPATA6L shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SPATA6L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
